Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France

Table 4

Health care utilization during active treatment.

	Second-Line				Third-Line
	Bortezomib-Containing Regimens		Lenalidomide-Containing Regimens		Bortezomib-Containing Regimens		Lenalidomide-Containing Regimens
	n		n		n		n
All patients, n ()	45	100.0	110	100.0	30	100.0	33	100.0
Inpatient hospitalizations
Had ≥ 1 hospitalization, n (%)	9	20.0	25	22.7	8	26.7	5	15.2
No. hospitalizations per person-year	0.19		0.15		0.43		0.20
Emergency department visits
Had ≥ 1 visit, n (%)	8	17.8	17	15.5	6	20.0	7	21.2
No. visits per person-year	0.19		0.15		0.32		0.47
Office visits
Had ≥ 1 visit, n (%)	8	17.8	35	31.8	8	26.7	5	15.2
No. visits per person-year	0.62		1.59		2.17		1.42
Hospital outpatient/day visits
Had ≥ 1 visit, n (%)	34	75.6	66	60.0	22	73.3	22	66.7
No. visits per person-year	6.03		3.99		12.16		6.38